跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2014-000440-15-GB
EUCTR2014-000440-15-GB进行中（未招募）1 期

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Acerta Pharma, BV0 个研究点目标入组 286 人开始时间: 2014年3月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
286
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Men and women = 18 years of age with a confirmed diagnosis of CLL/SLL, which has relapsed after, or been refractory to, = 2 previous treatments for CLL/SLL.
  • •2. Must have measurable CLL/SLL defined as = 1 lymph node = 2 cm as measured in the longest diameter.
  • •3. Active disease meeting = 1 of the following IWCLL 2008 criteria for requiring treatment:
  • •o Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets < 100,000/µL).
  • •o Massive (ie, = 6 cm below the left costal margin), progressive, or symptomatic splenomegaly.
  • •o Massive nodes (ie, = 10 cm in the longest diameter), progressive, or symptomatic lymphadenopathy.
  • •o Progressive lymphocytosis with an increase of > 50% over a 2-month period or a lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In subjects with initial blood lymphocyte counts of <30 X 109/L (30,000/µL), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded.
  • •o Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard therapy.
  • •o Constitutional symptoms documented in the subject's chart with supportive objective measures, as appropriate, defined as = 1 of the following disease-related symptoms or signs:
  • •?- Unintentional weight loss = 10% within the previous 6 months before Screening.
  • •? - Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without evidence of infection.
  • •? - Night sweats for > 1 month before screening without evidence of infection.
  • •4. ECOG performance status of = 2.
  • •5. Agreement to use highly effective methods of contraception
  • •during the study and for 2 days after the last dose of study
  • •drug if sexually active and able to bear or beget children.
  • •6. Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
  • •7. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local subject privacy
  • •regulations).
  • •Inclusion Criteria for Treatment Subgroups. Subjects meeting the following criteria will be eligible for the indicated Treatment Subgroups. In addition, Inclusion Criteria 2 to 8 from the previous apply to the Treatment Subgroups as well.
  • •1. Treatment Naive only: Men and women = 18 years of age with confirmed diagnosis of CLL/SLL, who require treatment per National Cancer Institute or International Working Group guidelines and a) do not want to receive
  • •chemoimmunotherapy or b) have comorbidities that would preclude chemoimmunotherapy.
  • •2. Ibrutinib Intolerant only: Men and women = 18 years of age with confirmed diagnosis of CLL/SLL who are not tolerating ibrutinib due to ibrutinib-related AEs.
  • •3. Richter's Syndrome and Prolymphocytic Leukemia Transformation only: Men and women = 18 years of age with biopsy proven DLBCL Richter's transformation or prolymphocytic leukemia transformation.
  • •4. Ibrutinib R/R only: Men and women = 18 years of age with confirmed diagnosis of CLL/SLL whose best response after 2 cycles of ibrutinib therapy was SD or nonr

排除标准

  • •1. Prior malignancy, except for adequately treated basal cell,
  • •squamous cell skin cancer or in situ cervical cancer.
  • •Subjects with other prior malignancies from which the
  • •subject has been disease free for = 2 years may be
  • •included if approved by the medical monitor.
  • •2. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.
  • •3. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) = 40%.
  • •4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass..
  • •5. Any immunotherapy within 4 weeks of first dose of study drug.
  • •6. For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
  • •7. Relapsed after, or refractory to, prior BTK inhibitor therapy (Note: Does not apply to Ibrutinib R/R or Richter's Syndrome Group).
  • •8. Any history of Richter's transformation (Note: Does not apply to Richter's Syndrome Group).
  • •9. Central nervous system (CNS) involvement by lymphoma.
  • •10. Grade = 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.
  • •11. Known history of human immunodeficiency virus (HIV) or serologic status indicating active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection or any uncontrolled active systemic infection. Subjects with hepatitis B core antibody positive who are surface antigen negative or who are hepatitis C antibody positive will need to have a negative polymerase chain reaction (PCR) result before enrollment. Those who are hepatitis B surface antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive will be excluded.
  • •12. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to autoimmune destruction within the screening period or requirement for high doses of steroids (> 20 mg daily of prednisone daily or equivalent).
  • •13. History of stroke or intracranial hemorrhage within 6 months prior to the first dose of study drug.
  • •14. Requires treatment with proton-pump inhibitors (eg, omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
  • •15. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 7 days of first dose of study drug.
  • •16. Major surgery within 4 weeks before first dose of study drug.
  • •17. ANC < 0.75 x 109/L or platelet count < 50 x 109/L unless there is bone marrow involvement.
  • •18. Total bilirubin > 1.5 x ULN (total bilirubin = 2.5 x ULN allowed in subjects with autoimmune hemolytic anemia that is otherwise controlled); AST or ALT > 3.0 x ULN unless disease related.
  • •19. Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN.
  • •20. Significant screening ECG abnormalities including 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, or QTc = 480 ms.
  • •21. Cardiac troponi

研究者

相似试验

进行中（未招募）
不适用
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with Leukemia or special types of LeukemiaChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL), Richter's Syndrome or Prolymphocytic LeukemiaMedDRA version: 18.0Level: LLTClassification code 10073483Term: B-cell prolymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10003910Term: B-cell small lymphocytic lymphoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10058728Term: Richter's syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2014-000440-15-DEAcerta Pharma BV240
招募中
2 期
A trial to see the effects of increased doses of ACP-196 (the test drug) in subjects with LeukemiaProlymphocytic LeukemiaChronic Lymphocytic Leukemia
2023-509346-35-00Acerta Pharma B.V.1
进行中（未招募）
不适用
A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of BMN 110 in Subjects with Mucopolysaccharidosis IVA (Morquio Syndrome)
EUCTR2008-007365-23-GBBioMarin Pharmaceutical Inc.
进行中（未招募）
1 期
A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid TumorsRelapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)MedDRA version: 20.0Level: LLTClassification code 10009963Term: Colon carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10007336Term: Carcinoma colon recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082179Term: Squamous cell carcinoma of head and neck metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-002177-25-ESektar Therapeutics78
进行中（未招募）
1 期
A study on NKTR-255 in combination with Cetuximab as salvage treatment for Solid TumorsRelapsed or refractory (R/R) head and neck squamous cell carcinoma (HNSCC) or colorectal carcinoma (CRC)MedDRA version: 22.0Level: LLTClassification code 10082179Term: Squamous cell carcinoma of head and neck metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10009963Term: Colon carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10007336Term: Carcinoma colon recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2021-002177-25-ITEKTAR THERAPEUTICS78